Yes, most of them can be reimbursed by medical insurance, and the price is also very high. Just cooperate with the doctor's treatment, regardless of the money. The general formula of medical insurance reimbursement is as follows: reimbursement amount = [total treatment expenses-deductible-self-funded part] _ reimbursement ratio (70%-90%) Note: deductible means that the treatment expenses exceed the minimum limit, and the deductible is different in different regions. The maximum amount of reimbursement, that is, the amount of money reimbursed, cannot exceed the maximum amount, and there are differences in different regions, usually hundreds of thousands.

First, how to reimburse medical insurance?

Medical insurance reimbursement process:

1. The agent submits the reimbursement documents and other materials to the social security agency for acceptance;

2. After receiving the application materials, the accepting department will complete the examination, settlement and payment on the same day;

3. After the social security agency reviews the materials and approves the application, the applicant receives the reimbursement form of social medical insurance medical expenses and submits it for reimbursement.

Legal basis:

Article 26 of People's Republic of China (PRC) Social Insurance Law

The basic medical insurance for employees, the new rural cooperative medical system and the basic medical insurance for urban residents shall be implemented in accordance with state regulations.

Article 28 of People's Republic of China (PRC) Social Insurance Law

Medical expenses that meet the basic medical insurance drug list, diagnosis and treatment items, medical service facilities standards and emergency rescue shall be paid by the basic medical insurance fund in accordance with state regulations.

Two. PD- 1

PD- 1 (programmed death receptor 1), also known as CD279 (differentiation cluster 279), is an important immunosuppressive molecule. By down-regulating the immune system's response to human cells, it can inhibit the inflammatory activity of T cells, regulate the immune system and promote self-tolerance. This can prevent autoimmune diseases, but it can also prevent the immune system from killing cancer cells.

20 18, 12, the first PD- 1 antibody drug cindilizumab injection for Hodgkin's lymphoma in China was approved for marketing. "Daboshu" was approved for listing, which marked the entry of anti-tumor immunotherapy into "China's innovative era". In 20 19, 1 1, daboshu (scientific name: Hindley monoclonal antibody injection) was listed as Class B in the National Drug List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance (version 20 19), becoming the only PD-/that entered the national medical insurance list.

20 19- 12, the domestic PD- 1 antibody drug-Baizean (common name: terelizumab injection) was approved for marketing, and the domestic tumor immunotherapy was further developed. Tilizumab is not only the first new anticancer drug independently developed by Baekje Shenzhou and approved to be listed in China, but also the first tumor immunotherapy drug of Baekje Shenzhou.